SLC5A2 and type 2 diabetes mellitus: Sodium glucose cotransporter 2 (SGLT2) inhibitors have newly emerged as an anti-hyperglycemic drug for type 2 diabetes mellitus (T2DM) by inhibiting glucose and sodium reabsorption in the kidney.